

# FEE TRANSMITTAL

Patent fees are subject to annual revision.

APR 18 2002

Complete if Known

Application Number	10/031,691
Filing Date	January 22, 2002
First Named Inventor	Uebele, et al.
Examiner Name	
Group Art Unit	
Attorney Docket Number	20499P

TOTAL AMOUNT OF PAYMENT

\$130

## METHOD OF PAYMENT (Check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number

Deposit Account Name

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	740	Utility filing fee	<input type="text"/>
106	330	Design filing fee	<input type="text"/>
108	740	Reissue filing fee	<input type="text"/>
114	160	Provisional filing fee	<input type="text"/>
SUBTOTAL(1)			<input type="text" value="\$0"/>

### 2. EXTRA CLAIM FEES

	Extra	Fee from below	Fee Paid
Total Claims <input type="text" value="20"/>	** = <input type="text" value="0"/>	x \$18 =	<input type="text" value="0"/>
Independent Claims <input type="text" value="3"/>	** = <input type="text" value="0"/>	x \$84 =	<input type="text" value="0"/>
Multiple Dependent Claims		\$280 =	<input type="text"/>

\*\*or number previously paid, if greater; For Reissues, see below


Large Fee Code	Entity Fee (\$)	Fee Description
103	18	Claims in excess of 20
102	84	Independent claims in excess of 3
104	280	Multiple dependent claim, if not paid
109	84	**Reissue independent claims over original patent
110	18	**Reissue claims in excess of 20 and over original patent
SUBTOTAL(2)		<input type="text" value="\$0"/>

### 3. ADDITIONAL FEES


Large Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
105	130	Surcharge - late filing fee or oath	<input type="text" value="130"/>
147	2,520	For filing a request for reexamination	<input type="text"/>
115	110	Extension for reply within first month	<input type="text"/>
116	400	Extension for reply within second month	<input type="text"/>
117	920	Extension for reply within third month	<input type="text"/>
118	1,440	Extension for reply within fourth month	<input type="text"/>
128	1,960	Extension for reply within fifth month	<input type="text"/>
119	320	Notice of Appeal	<input type="text"/>
120	320	Filing a brief in support of an appeal	<input type="text"/>
121	280	Request for oral hearing	<input type="text"/>
140	110	Petition to revive - unavoidable	<input type="text"/>
141	1,280	Petition to revive - unintentional	<input type="text"/>
142	1,280	Utility issue fee (or reissue)	<input type="text"/>
143	460	Design issue fee	<input type="text"/>
122	130	Petitions to the Commissioner	<input type="text"/>
123	50	Petitions related to provisional applications	<input type="text"/>
126	180	Submission of Information Disclosure Statement	<input type="text"/>
581	40	Recording each patent assignment per property (times number of properties)	<input type="text"/>
146	740	Filing a submission after final rejection (37 CFR 1.129(a))	<input type="text"/>
149	740	For each additional invention to be examined (37 CFR 1.129(b))	<input type="text"/>
179	740	Request for Continued Examination (RCE)	<input type="text"/>
Other fee (specify) _____			<input type="text"/>
Other fee (specify) _____			<input type="text"/>
SUBTOTAL(3)			<input type="text" value="\$130"/>

## SUBMITTED BY

## Complete (if applicable)

Typed or Printed Name	Joseph A. Coppola	Reg. Number	38,413
Signature		Date	04/12/2002
		Deposit Account User ID	

Application Number: 10/031,691  
Filing Date: 01/22/2002  
First Named Inventor: Uebele, et al.  
Group Art Unit: \_\_\_\_\_  
Examiner Name: \_\_\_\_\_  
Attorney Docket Number: 20499P



**FIRST CLASS MAIL CERTIFICATE**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE APPEARING BELOW.

**MERCK & CO., INC.**

MAILED BY

Karen York

DATE

April 12, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

APR 18 2002

Commissioner for Patents, Box PC1  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO
10/031,691	Victor Uebele	20499P

Merck & Company  
Patent Department, RY60-30  
P O Box 2000  
126 East Lincoln Avenue  
Rahway, NJ 07065-0970

*Oath &  
Declaration  
& Sequence Requirements  
Due  
6/3/02*

INTERNATIONAL APPLICATION NO
PCT/US00/19585
LA FILING DATE
PRIORITY DATE

07/18/2000

CONFIRMATION NO. 8269

371 FORMALITIES LETTER



\*OC000000007774557\*

Date Mailed: 04/03/2002

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

LAMONT M HUNTER

Telephone: (703) 305-3686

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/031,691	PCT/US00/19585	20499P

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Uebele, et al.
Serial No.:	10/031,691 - Case No.: 20499P
Filed:	January 22, 2002
For:	NOVEL HUMAN CALCIUM SENSITIVE POTASSIUM CHANNEL

Art Unit:

Examiner:

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF SEQUENCE STATEMENT

Sir:

Please insert the enclosed Sequence Listing in paper and computer readable form into the above-identified application. The Sequence Listing does not contain new matter. The contents of the paper and computer readable forms of the Sequence Listing are the same.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Karey York Date 4/12/02  
MERCK & CO., INC.

Respectfully submitted,

By Joseph A. Coppola  
Joseph A. Coppola  
Reg. No. 38,413  
Attorney for Applicant

MERCK & CO., INC.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-6734

Date: APRIL 12, 2002